EFFECTS OF PEMBROLIZUMAB ON THE TUMOR MICROENVIRONMENT (TME) AFTER ONE PRESURGERY TREATMENT CYCLE IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER (TNBC): PHASE 1B KEYNOTE-173 STUDY

被引：2
|
作者：
Schmid, Peter [1 ]
Park, Yeon Hee [2 ]
Munoz-Couselo, Eva [3 ]
Kim, Sung-Bae [4 ]
Sohn, Joohyuk [5 ]
Im, Seock-Ah [6 ]
Holgado, Esther [7 ]
Foukakis, Theodoros [8 ,9 ]
Kuemmel, Sherko [10 ]
Dent, Rebecca [11 ]
Sun, Yuan [12 ]
Huang, Lingkang [12 ]
Yearley, Jennifer [12 ]
Jelinic, Petar [12 ]
Karantza, Vassiliki [12 ]
Cortes, Javier [3 ]
机构：
[1] Ctr Expt Canc Med, London, England
[2] Samsung Med Ctr, Seoul, South Korea
[3] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[4] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[5] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[6] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul Natl Univ Hosp, Seoul, South Korea
[7] Ramon y Cajal Univ, Madrid, Spain
[8] Karolinska Inst, Solna, Sweden
[9] Karolinska Univ Hosp, Theme Canc, Breast Canc Ctr, Solna, Sweden
[10] Kliniken Essen Mitte, Essen, Germany
[11] Int Breast Canc Ctr Quironsalud Grp, Singapore, Singapore
[12] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.338
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
338
引用
收藏
页码：A364 / A364
页数：1
相关论文
共 50 条
  • [31] Biomarker analysis of phase II pembrolizumab maintenance treatment after chemotherapy response in patients with HER2-negative inflammatory breast cancer and triple-negative breast cancer
    Iwase, Toshiaki
    Alexander, Angela
    Cohen, Evan N.
    Gao, Hui
    Chiv, Vivian Y.
    Kai, Megumi
    Kida, Kumiko
    Krishnamurthy, Savitri
    Liu, Dianne
    Shen, Yu
    Ramirez, David Luis
    Reuben, Alexandre
    Tripathy, Debu
    Booser, Daniel J.
    Moulder, Stacy L.
    Yam, Clinton
    Valero, Vicente
    Lim, Bora
    Reuben, James M.
    Ueno, Naoto T.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] KEYNOTE-522: Phase III study of pembrolizumab (pembro) 1 chemotherapy (chemo) vs placebo 1 chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC)
    Schmid, P.
    Cortes Castan, J.
    Bergh, J.
    Pusztai, L.
    Denkert, C.
    Verma, S.
    McArthur, H. L.
    Zhao, J.
    Aktan, G.
    Dang, T.
    Dent, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] Phase 1B/2 clinical trial targeting nitric oxide in the treatment of chemo-refractory metaplastic triple-negative breast cancer patients
    Puri, Akshjot
    Ordonez, Adriana
    Anselme, Ann C.
    Guzman, Liliana
    Niravath, Polly
    Chang, Jenny C.
    CANCER RESEARCH, 2022, 82 (04)
  • [34] A study of circulating biomarkers of angiogenesis and inflammation in ER plus breast cancer (BC) versus triple-negative breast cancer (TNBC) patients enrolled in a phase II study of preoperative treatment with 1 cycle of Bevacizumab followed by standard chemo
    Duda, Dan G.
    Tolaney, Sara M.
    Ancukiewicz, Marek
    Winer, Eric P.
    Krop, Ian E.
    Jain, Rakesh K.
    CANCER RESEARCH, 2013, 73 (08)
  • [35] KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
    Schmid, P.
    Cortes, J.
    Dent, R.
    Pusztai, L.
    McArthur, H. L.
    Kuemmel, S.
    Bergh, J.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Foukakis, T.
    Fasching, P. A.
    Cardoso, F.
    Jia, L.
    Karantza, V.
    Zhao, J.
    Aktan, G.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 853 - 854
  • [36] Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (OC) (TOPACIO/Keynote-162)
    Konstantinopoulos, P. A.
    Sachdev, J. C.
    Schwartzberg, L.
    Matulonis, U. A.
    Sun, P.
    Wang, J. Y.
    Guo, W.
    Bobilev, D.
    Aktan, G.
    Karantza, V.
    Dezube, B.
    Vinayak, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] A PHASE 1B MULTI-TUMOR COHORT STUDY OF CABOZANTINIB PLUS ATEZOLIZUMAB IN ADVANCED SOLID TUMORS: RESULTS OF THE TRIPLE-NEGATIVE BREAST CANCER, OVARIAN CANCER, AND ENDOMETRIAL CANCER COHORTS
    Winer, Ira
    Wimalasingham, Akhila
    Baranda, Joaquina
    Santoro, Armando
    Spencer, Kristen
    Baldini, Capucine
    Duska, Linda
    Subbiah, Vivek
    Patel, Sandip
    Khrizman, Polina
    Van Lancker, Griet
    Andrianova, Lana
    Atwal, Sumandeep
    Sharma, Keerti
    Manso, Luis
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A562 - A562
  • [38] RESULTS OF THE FIRST RANDOMIZED PHASE II STUDY OF CATIONIC LIPOSOMAL PACLITAXEL (ENDOTAG™-1) TARGETING TUMOR ENDOTHELIAL CELLS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER (TNBC)
    Awada, A.
    Bondarenko, I. N.
    Tarasova, O.
    Bonneterre, J.
    Nowara, E.
    Ferrero, J. M.
    Bakshi, A. V.
    Glasschroeder, B.
    Elsasser, U.
    Piccart, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 5 - 6
  • [39] Phase 1b study of heat shock protein 90 inhibitor onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173)
    Wesolowski, Robert
    Lustberg, Maryam B.
    Mrozek, Ewa
    Layman, Rachel
    Reinbolt, Raquel
    Poi, Ming
    Osman, Nadia
    Lively, Andrea
    Stephens, Julie
    Greyer, Michael
    Ramaswamy, Bhuvaneswari
    CANCER RESEARCH, 2016, 76
  • [40] Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia
    Yusof, M. Md
    Cescon, D. W.
    Rugo, H. S.
    Im, S-A.
    Gallardo, C.
    Lipatov, O.
    Barrios, C. H.
    Holgado, E.
    Iwata, H.
    Masuda, N.
    Gokmen, E.
    Loi, S.
    Guo, Z.
    Jensen, E.
    Aktan, G.
    Karantza, V.
    Schmid, P.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1257 - S1257
12345